eMIMS New Product
New drug - Tasigna
23-Jun-08
Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome positive chronic myelogenous leukaemia (CML).
Treatment is indicated for adults with chronic-phase and accelerated-phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.
Further information: Novartis 01276 692255
Quick search - use * for an abbreviated search, eg nico*
Tools
Latest Guidelines
- Osteoporotic Fragility Fractures in Postmenopausal Women: Primary Prevention (NICE)
- Osteoporotic Fragility Fractures in Postmenopausal Women: Secondary Prevention (NICE)
- VTE, Prevention of: Dabigatran (NICE)
- Influenza Prophylaxis: Oseltamivir, Amantadine and Zanamivir (NICE)
- Hepatitis B, Chronic: Entecavir (NICE)
GMS Contract Action Plan
Jobs
Job of the Week
- Full Time / Part Time Salaried GPs Yorkshire and Humberside
- Salaried Doctor East of England
- Salaried General Practitioner(s) East Midlands
- Partner East of England
- Partner Yorkshire and Humberside
- Salaried GP North West England
- salaried GP/retainer North West England
- Medical Partnership in Ireland Republic of Ireland
- Part -Time Salaried GP Yorkshire and Humberside
- Full Time Salaried GP Yorkshire and Humberside
Comments
Only registered users may comment. Log in now or register for a free account.